Lung cancer specialist Mark Socinski, at the University of Pittsburgh Cancer Institute, discusses VeriStrat testing and how it may be useful in the diagnosis of non-small cell lung cancer.
Mark Socinski, co-leader of the lung cancer program at the University of Pittsburgh Cancer Institute, discusses VeriStrat testing and how it may be useful in the diagnosis of non-small cell lung cancer (NSCLC).
VeriStrat is a blood test that examines protein patterns and distinguishes which patients with NSCLC would see minimal benefit from EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) and Iressa (gefitinib). Socinski uses results from a VeriStrat test to exclude these choices from a patient’s treatment plan.
The test also includes a prognostic factor, advising practitioners that patients who test VeriStrat “poor" are likely to have a poor prognosis, versus patients who test VeriStrat “good."
Though he does not order VeriStrat testing for all patients in the second and/or third-line setting of NSCLC, Socinski says it is a useful tool.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More